Oxidoreductases Acting on CH-CH Group Donors
"Oxidoreductases Acting on CH-CH Group Donors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of enzymes which includes all dehydrogenases acting on carbon-carbon bonds. This enzyme group includes all the enzymes that introduce double bonds into substrates by direct dehydrogenation of carbon-carbon single bonds.
| Descriptor ID |
D044925
|
| MeSH Number(s) |
D08.811.682.660
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oxidoreductases Acting on CH-CH Group Donors".
Below are MeSH descriptors whose meaning is more specific than "Oxidoreductases Acting on CH-CH Group Donors".
This graph shows the total number of publications written about "Oxidoreductases Acting on CH-CH Group Donors" by people in this website by year, and whether "Oxidoreductases Acting on CH-CH Group Donors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oxidoreductases Acting on CH-CH Group Donors" by people in Profiles.
-
DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation. Elife. 2024 Jul 08; 12.
-
ENT1 blockade by CNX-774 overcomes resistance to DHODH inhibition in pancreatic cancer. Cancer Lett. 2023 01 01; 552:215981.
-
Lathosterolosis: An Extremely Rare Inherited Condition Associated With Progressive Liver Disease. J Pediatr Gastroenterol Nutr. 2019 11; 69(5):e142-e145.
-
Pyrenyl-carbon nanostructures for scalable enzyme electrocatalysis and biological fuel cells. Analyst. 2018 Jun 11; 143(12):2876-2882.
-
Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Nov; 75(11):1909-1916.